Cost-benefit of dementia insurance for cognitively-unimpaired <i>APOE</i> ε4 homozygotes: A simulation study
Dementia insurance may be relatively more cost-beneficial for asymptomatic ε4-homozygotes in their 60 s or older compared to other genotypes over policy periods of 10 years or longer. However, it does not represent a clear financial gain for the insured, highlighting the need for careful consideration. Our study provides an important basis for further investigating the advantages and limitations of dementia insurance for individuals with high-risk gene.
Authors
- Kenichiro Sato (ORCID: https://orcid.org/0000-0003-4351-9526)
- Yoshiki Niimi (ORCID: https://orcid.org/0000-0002-2556-8167)
- Takeshi Iwatsubo (ORCID: https://orcid.org/0000-0003-1160-8129)
- Ryoko Ihara (ORCID: https://orcid.org/0000-0001-8770-3283)
- Shigeru Nakashima
Institutions
- University of Tokyo Hospital (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal of Alzheimer s Disease Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/25424823251372925
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science